by Rod Raynovich | Jun 20, 2011 | 2024-25 Life Science Portfolios, BIOgraph
NASDAQ stocks rallied today just off March 2011 QQQ bottoms led by large cap biotech stocks.The NASDAQ 100 is up 0.6% led by Biogen Idec(BIIB) up 4.26%, Celgene (CELG) up 3.27%, and Gilead (GILD) up 1.5%.The rally would be stronger were it not for weak tech stocks...
by Rod Raynovich | Jun 17, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Busy Day Today -Overall a Lot of Green Screen The diagnostics and tools sector has seen resilience over the past 30 days as the market corrected 7% or more.Bellwether large cap tools stocks with revenue growth such as ILMN,NEOG, TMO have held up well helped by M&A...
by Rod Raynovich | Jun 10, 2011 | 2024-25 Life Science Portfolios, BIOgraph
All major indices and sectors sold off today making it 7 bad days out of 8 and a 6.37% correction in the S&P 500 over 30 days. The NASDAQ is now down 7.94% since May 11. Remember “sell in May and go away” ? Things were not much better in biotech-land...
by Rod Raynovich | Jun 8, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Stocks Down for Sixth Straight Session: Biotechs still up Over 10% YTD As we wind down from ASCO news with few catalysts ahead, investors and traders will regroup and rebalance their portfolios. The NASDAQ index is down 21 pts off 0.77% and component biotech stocks...
by Rod Raynovich | Jun 7, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biopharmaceutical stocks got a boost today from a rally in NASDAQ stocks and some positive news on cancer drugs from ASCO. The IBB ($106.36) was up 1.6% off its YTD and all time high of $110 and a nice rally after five days of weakness.The XBI was also up 1.97%. Many...
by Rod Raynovich | Jun 6, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Speculation in small cap biopharmaceutical stocks has peaked and we urged weeks ago to raise cash positions to 10-15%. The ASCO “sell on the news effect” has continued today with some high fliers off significantly: Exelixis (EXEL $8.95) is off 18% after...
by Rod Raynovich | May 31, 2011 | 2024-25 Life Science Portfolios, BIOgraph
The life science market continued to show resilience today with a few big movers and a bidding up of large cap drugs such as Johnson and Johnson (JNJ $67.15), Novartis (NVS $64.24), Pfizer(PFE $21.21) and Sanofi-Aventis (SNY $39.42). Foreign drug companies fared...
by Rod Raynovich | May 27, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Our recent article on biotech investing and ETF’s in general are posted on Investor Uprising. Note to get the article on the right side of the page you need to register at no charge for Investor Uprising. Investor Uprising – IU Education – Guide to...
by Rod Raynovich | May 25, 2011 | 2024-25 Life Science Portfolios, BIOgraph
A bull market in life science stocks has revved up news for the upcoming ASCO Meeting on June 3 in Chicago. We will provide limited coverage of stocks to watch and scientific articles of interest. However it is clear that many PR shops and newsletters are busy...
by Rod Raynovich | May 23, 2011 | 2024-25 Life Science Portfolios, BIOgraph
It was a nasty day from the beginning but losses abated as the day wore on. The NASDAQ was off 1.68%, the Dow down 1.05% and the S&P down 1.15% to 1317. The S&P held trend lines in the 1312-1315 range. Biotech ETF’s were also losers IBB off 1.5%, FBT off...
